These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 18842713)

  • 21. Increased susceptibility of human respiratory syncytial virus to neutralization by anti-fusion protein antibodies on adaptation to replication in cell culture.
    Marsh R; Connor A; Gias E; Toms GL
    J Med Virol; 2007 Jun; 79(6):829-37. PubMed ID: 17457900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characteristics of immunity induced by viral antigen or conferred by antibody via different administration routes.
    Matsuoka T; Okamoto Y; Matsuzaki Z; Endo S; Ito E; Tsutsumi H; Williamson RA; Sakurai H; Burton DR; Saito I
    Clin Exp Immunol; 2002 Dec; 130(3):386-92. PubMed ID: 12452827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles.
    Garlapati S; Garg R; Brownlie R; Latimer L; Simko E; Hancock RE; Babiuk LA; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Vaccine; 2012 Jul; 30(35):5206-14. PubMed ID: 22713718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intracellular processing of the human respiratory syncytial virus fusion glycoprotein: amino acid substitutions affecting folding, transport and cleavage.
    Anderson K; Stott EJ; Wertz GW
    J Gen Virol; 1992 May; 73 ( Pt 5)():1177-88. PubMed ID: 1375280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Potential of Prefusion RSV F-specific Antibodies.
    Rossey I; McLellan JS; Saelens X; Schepens B
    Trends Microbiol; 2018 Mar; 26(3):209-219. PubMed ID: 29054341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in mice.
    Murata Y; Catherman SC
    Vaccine; 2012 Aug; 30(36):5382-8. PubMed ID: 22728222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-propagating, recombinant vesicular stomatitis virus vectors encoding respiratory syncytial virus proteins generate potent humoral and cellular immunity against RSV and are protective in mice.
    Johnson JE; McNeil LK; Megati S; Witko SE; Roopchand VS; Obregon JH; Illenberger DM; Kotash CS; Nowak RM; Braunstein E; Yurgelonis I; Jansen KU; Kalyan NK; Sidhu MK
    Immunol Lett; 2013 Feb; 150(1-2):134-44. PubMed ID: 23261719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice.
    Haynes LM; Caidi H; Radu GU; Miao C; Harcourt JL; Tripp RA; Anderson LJ
    J Infect Dis; 2009 Aug; 200(3):439-47. PubMed ID: 19545210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Baculovirus expression of the respiratory syncytial virus fusion protein using Trichoplusia ni insect cells.
    Parrington M; Cockle S; Wyde P; Du RP; Snell E; Yan WY; Wang Q; Gisonni L; Sanhueza S; Ewasyshyn M; Klein M
    Virus Genes; 1997; 14(1):63-72. PubMed ID: 9208456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Research Progress in the F Gene and Protein of the Respiratory Syncytial Virus].
    Zhang F; Xie Z
    Bing Du Xue Bao; 2015 Mar; 31(2):201-6. PubMed ID: 26164949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conformational Flexibility in Respiratory Syncytial Virus G Neutralizing Epitopes.
    Fedechkin SO; George NL; Nuñez Castrejon AM; Dillen JR; Kauvar LM; DuBois RM
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31852779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.
    Kahn JS; Roberts A; Weibel C; Buonocore L; Rose JK
    J Virol; 2001 Nov; 75(22):11079-87. PubMed ID: 11602747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A recombinant varicella vaccine harboring a respiratory syncytial virus gene induces humoral immunity.
    Murakami K; Matsuura M; Ota M; Gomi Y; Yamanishi K; Mori Y
    Vaccine; 2015 Nov; 33(45):6085-92. PubMed ID: 26116253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Respiratory syncytial virus and neutrophil activation.
    Bataki EL; Evans GS; Everard ML
    Clin Exp Immunol; 2005 Jun; 140(3):470-7. PubMed ID: 15932508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection.
    Detalle L; Stohr T; Palomo C; Piedra PA; Gilbert BE; Mas V; Millar A; Power UF; Stortelers C; Allosery K; Melero JA; Depla E
    Antimicrob Agents Chemother; 2016 Jan; 60(1):6-13. PubMed ID: 26438495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines.
    Sakurai H; Williamson RA; Crowe JE; Beeler JA; Poignard P; Bastidas RB; Chanock RM; Burton DR
    J Virol; 1999 Apr; 73(4):2956-62. PubMed ID: 10074145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antigenic Fingerprinting of Respiratory Syncytial Virus (RSV)-A-Infected Hematopoietic Cell Transplant Recipients Reveals Importance of Mucosal Anti-RSV G Antibodies in Control of RSV Infection in Humans.
    Fuentes S; Hahn M; Chilcote K; Chemaly RF; Shah DP; Ye X; Avadhanula V; Piedra PA; Golding H; Khurana S
    J Infect Dis; 2020 Feb; 221(4):636-646. PubMed ID: 31745552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of recombinant influenza A virus as a vector expressing respiratory syncytial virus fusion protein epitopes.
    Zhang P; Gu H; Bian C; Liu N; Li Z; Duan Y; Zhang S; Wang X; Yang P
    J Gen Virol; 2014 Sep; 95(Pt 9):1886-1891. PubMed ID: 24914066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection.
    Haynes LM; Tonkin J; Anderson LJ; Tripp RA
    J Virol; 2002 Jul; 76(14):6873-81. PubMed ID: 12072488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence and Significance of Substitutions in the Fusion Protein of Respiratory Syncytial Virus Resulting in Neutralization Escape From Antibody MEDI8897.
    Zhu Q; Lu B; McTamney P; Palaszynski S; Diallo S; Ren K; Ulbrandt ND; Kallewaard N; Wang W; Fernandes F; Wong S; Svabek C; Moldt B; Esser MT; Jing H; Suzich JA
    J Infect Dis; 2018 Jul; 218(4):572-580. PubMed ID: 29617879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.